Moffitt Cancer Center advances Anixa ovarian CAR-T trial without dose-limiting toxicity
Anixa's ovarian cancer CAR-T inventor will deliver a November keynote as lira-cel advances through Phase 1 dose escalation. Preliminary findings include four patients surviving more than one year and an initial 90-day stable disease observation, but controlled efficacy evidence is not yet available.